# Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

> **NCT02663622** · PHASE2 · COMPLETED · sponsor: **Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 44 (actual)

## Conditions studied

- Graft Versus Host Disease
- Hematopoietic Stem Cell Transplantation
- Leukemia

## Interventions

- **DRUG:** Efprezimod alfa
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02663622
- **Lead sponsor:** Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-19
- **Primary completion:** 2020-06-08
- **Final completion:** 2021-05-18
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663622, "Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02663622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*